Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNF 180 Life Sciences	$4.81 -8.0%	$2.73	$0.66 ▼ $17.75	$29.05M	0.38	22.03 million shs	9.03 million shs
ENLV Enlivex Therapeutics	$1.05 +1.9%	$1.26	$0.81 ▼ $2.10	$24.83M	0.8	256,951 shs	887,884 shs
INAB IN8bio	$2.26 +0.9%	$2.23	$1.98 ▼ $17.64	$10.26M	0.01	165,134 shs	44,705 shs
SLGL Sol-Gel Technologies	$22.67 -12.1%	$10.68	$4.01 ▼ $26.89	$63.16M	1.21	23,744 shs	91,055 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNF 180 Life Sciences	-25.71%	-31.27%	+136.65%	+455.14%	+173.82%
ENLV Enlivex Therapeutics	-6.36%	-42.13%	-12.71%	+5.64%	-16.26%
INAB IN8bio	+1.36%	-6.67%	-5.49%	-48.47%	-86.23%
SLGL Sol-Gel Technologies	+40.22%	+69.18%	+177.12%	+239.92%	+330.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNF 180 Life Sciences	0.5317 of 5 stars	0.0	2.0	2.9	1.7	0.0
ENLV Enlivex Therapeutics	3.3019 of 5 stars	3.7	5.0	2.9	0.8	0.6
INAB IN8bio	3.8467 of 5 stars	3.5	5.0	3.0	2.5	1.3
SLGL Sol-Gel Technologies	1.0849 of 5 stars	0.0	3.0	4.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNF 180 Life Sciences	0.00	N/A	N/A	N/A
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	852.38% Upside
INAB IN8bio	3.00	Buy	$180.00	7,864.60% Upside
SLGL Sol-Gel Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INAB, ENLV, SLGL, and ATNF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/14/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/12/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	$2.91 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
SLGL Sol-Gel Technologies	$23.93M	2.64	N/A	N/A	$11.44 per share	1.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNF 180 Life Sciences	-$6.17M	-$15.07	N/A	∞	N/A	N/A	-141.25%	-80.77%	N/A
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
INAB IN8bio	-$30.44M	-$9.11	N/A	N/A	N/A	N/A	-184.97%	-126.75%	N/A
SLGL Sol-Gel Technologies	-$10.58M	-$1.23	N/A	N/A	N/A	-14.25%	-11.80%	-9.39%	N/A

Latest INAB, ENLV, SLGL, and ATNF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/15/2025	Q2 2025	SLGL Sol-Gel Technologies	-$0.67	$4.17	+$4.84	$4.17	$2.86 million	$17.26 million
8/7/2025	Q2 2025	INAB IN8bio	-$1.50	-$1.24	+$0.26	-$1.24	N/A	N/A
7/23/2025	Q2 2025	ATNF 180 Life Sciences	N/A	-$0.30	N/A	-$0.30	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNF 180 Life Sciences	N/A	0.58	0.58
ENLV Enlivex Therapeutics	N/A	7.20	7.20
INAB IN8bio	0.01	7.03	7.03
SLGL Sol-Gel Technologies	N/A	7.32	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNF 180 Life Sciences	4.07%
ENLV Enlivex Therapeutics	1.02%
INAB IN8bio	92.05%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
ATNF 180 Life Sciences	38.20%
ENLV Enlivex Therapeutics	12.28%
INAB IN8bio	15.50%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNF 180 Life Sciences	7	6.04 million	3.73 million	No Data
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
INAB IN8bio	20	4.54 million	3.84 million	Not Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable

INAB, ENLV, SLGL, and ATNF Headlines

Recent News About These Companies

Sol Gel Technologies trading halted, volatility trading pause

August 22 at 1:42 PM | msn.com

Sol-Gel Stock Delivers Over 150% Gain - Can The Upcoming Q4 Clinical Data Readout Sustain The Rally?

August 21 at 5:50 AM | rttnews.com

Sol-Gel Technologies Reports Strong Q2 2025 Results

August 20 at 4:20 AM | msn.com

Sol-Gel Technologies (NASDAQ:SLGL) Trading Up 4.3% on Better-Than-Expected Earnings

August 20 at 2:35 AM | americanbankingnews.com

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 15, 2025 | globenewswire.com

Sol-Gel Technologies Ltd. (SLGL) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Sol-Gel Technologies Ltd. (SLGL) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

SLGL Sol-Gel Technologies Ltd. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Sol-Gel Technologies Ltd

June 21, 2025 | morningstar.comM

Sol Gel Tech Stock Price History

June 1, 2025 | investing.com

Sol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | finanznachrichten.de

Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic

May 23, 2025 | msn.com

Sol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D Expenses

May 23, 2025 | quiverquant.comQ

Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | globenewswire.com

Insider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of Shares

May 3, 2025 | uk.finance.yahoo.com

This Sol-Gel Technologies Insider Increased Their Holding In The Last Year

May 2, 2025 | finance.yahoo.com

Sol-Gel Announces Reverse Share Split

May 1, 2025 | globenewswire.com

Sol-Gel, Mayne Pharma enter product purchase agreement

April 17, 2025 | markets.businessinsider.com

Sol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.

April 17, 2025 | finanznachrichten.de

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

April 17, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INAB, ENLV, SLGL, and ATNF Company Descriptions

180 Life Sciences NASDAQ:ATNF

$4.81 -0.42 (-8.03%)

As of 08/21/2025

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Enlivex Therapeutics NASDAQ:ENLV

$1.05 +0.02 (+1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$1.03 -0.02 (-1.43%)

As of 07:15 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

IN8bio NASDAQ:INAB

$2.26 +0.02 (+0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$2.32 +0.06 (+2.48%)

As of 06:57 PM Eastern

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Sol-Gel Technologies NASDAQ:SLGL

$22.67 -3.13 (-12.13%)

Closing price 04:00 PM Eastern

Extended Trading

$22.20 -0.47 (-2.07%)

As of 07:16 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time